<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04963218</url>
  </required_header>
  <id_info>
    <org_study_id>21-003530</org_study_id>
    <nct_id>NCT04963218</nct_id>
  </id_info>
  <brief_title>A Multi-Center Study of Detection of Low Ventricular Ejection Fraction</brief_title>
  <official_title>A Multicenter Study of Detection of Low Ventricular Ejection Fraction (LVEF) â‰¤ 40% Based on Point-of-Care 12- Lead ECG Data</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mayo Clinic</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Anumana, Inc.</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Mayo Clinic</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a multi-site, retrospective study to evaluate the performance of a locked AI-based&#xD;
      algorithm for detection of left ventricular systolic dysfunction. A prerequisite for&#xD;
      inclusion of subjects from each institution will be the availability of at least one digital&#xD;
      12-lead ECG paired with an echocardiogram with LVEF information within 30 days of the date of&#xD;
      the ECG. The AI-ECG LVSD algorithm will be applied on all ECGs and diagnostic performance&#xD;
      features for the detection of LVSD will be estimated using the provided paired LVEF value&#xD;
      (Low LVEF as the reference label). Performance will also be assessed in subgroups of subjects&#xD;
      determined by demographic and clinical factors.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Following institutional review board approval, 12,000 12-lead ECG's paired with an&#xD;
      echocardiogram with LVEF information within 30 days of the date of the ECG will be collected&#xD;
      across three enrolled sites. Each site will provide data from up to 4000 enrolled subjects&#xD;
      that meet the inclusion criteria. No other demographic characteristics or enrichment will be&#xD;
      considered in the selection of subjects in order to best represent the general population for&#xD;
      that site. Sites will securely transfer the data to a centralized repository for processing.&#xD;
&#xD;
      Once data is collected, the device will be used to analyze the ECG data for all enrolled&#xD;
      subjects without reference or access to the echocardiogram data. The device will display a&#xD;
      binary 36 prediction of the likelihood of LVEF less than or equal to 40%. Results will be&#xD;
      compared to the echocardiogram reference standard in accordance with the statistical analysis&#xD;
      plan.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 30, 2021</start_date>
  <completion_date type="Anticipated">December 31, 2021</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Established Diagnostic Performance</measure>
    <time_frame>1 month</time_frame>
    <description>Number of participants with presence of EF less than of equal to 40% identified by 12-lead AI ECG algorithm</description>
  </primary_outcome>
  <enrollment type="Anticipated">12000</enrollment>
  <condition>Cardiac Disease</condition>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>AI Algorithm to detect LVEF in ECG</intervention_name>
    <description>A clinical decision support software as a medical device that detects whether a patient has LVEF less than or equal to 40% based upon the input of one or more ECG vectors at the point-of-care.</description>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Adult subjects with or without known cardiac disease who are either inpatients or&#xD;
        outpatients with ECGs and an echocardiogram within 30-days of the ECG date.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        - Adult subjects with or without known cardiac disease who are either inpatients or&#xD;
        outpatients with ECGs and an echocardiogram within 30-days of the ECG date.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  No research authorization provided&#xD;
&#xD;
          -  An ECG signal shorter than 10 seconds or that is not interpretable&#xD;
&#xD;
          -  An echocardiogram is considered technically challenging&#xD;
&#xD;
          -  Only qualitative interpretation of left ventricular systolic function available (i.e.,&#xD;
             &quot;decreased EF&quot;) without a numerical value.&#xD;
&#xD;
          -  A paced rhythm&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>99 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Peter Noseworthy, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Mayo Clinic</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Tasha M McDevitt</last_name>
    <phone>507-266-7948</phone>
    <email>Mcdevitt.Tasha@mayo.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>Beth Israel Deacon Medical Center</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tasha m McDevitt</last_name>
      <phone>507-266-7948</phone>
      <email>Mcdevitt.Tasha@mayo.edu</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://www.mayo.edu/research/clinical-trials</url>
    <description>Mayo Clinic Clinical Trials</description>
  </link>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>July 1, 2021</study_first_submitted>
  <study_first_submitted_qc>July 14, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">July 15, 2021</study_first_posted>
  <last_update_submitted>September 10, 2021</last_update_submitted>
  <last_update_submitted_qc>September 10, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 14, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Mayo Clinic</investigator_affiliation>
    <investigator_full_name>Peter A. Noseworthy, M.D.</investigator_full_name>
    <investigator_title>Professor of Medicine</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Diseases</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

